What's new?We have described wearable cardioverter-defibrillator (WCD) use \>90 days in a large cohort of patients prescribed the WCD in a real-life registry.We showed a lower incidence of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) events, WCD treated VT/VF events and non-sustained VT events with WCD use \>90 vs. WCD use ≤90 days.Non-ischaemic patients had similar rates of sustained VT/VF events during WCD use \>90 vs. ≤90 days, while most of these events terminated spontaneously.One-third of the patients with extended WCD use improved their ejection fraction (EF), and they were not implanted with an implantable cardioverter-defibrillator.Congenital/inherited patients were less likely to improve their EF even with prolonged use of WCD \> 90 days.

Introduction
============

Wearable cardioverter-defibrillators (WCDs) are currently used in patients at risk for sudden cardiac death (SCD) who are temporarily unable to receive an implantable cardioverter-defibrillator (ICD), or when the risk for SCD may improve over time.[@euy091-B1] Wearable cardioverter-defibrillators are safe and effective in terminating VT/VF events and provide protection against SCD while awaiting implantation of an ICD, or during a time of risk stratification.[@euy091-B4]^,^[@euy091-B5] Current recommendations on the use of the WCD suggest 40 or 90 days as the mandatory ICD waiting periods following a myocardial infarction (MI) or percutaneous coronary intervention (PCI)/coronary artery bypass graft surgery (CABG), respectively, and 90-day wait period for newly diagnosed non-ischaemic cardiomyopathy patients.

Little is known about WCD use \>90 days and its outcomes. There might be a conceivable benefit from an extended use of the WCD in certain populations, especially in patients with non-ischaemic cardiomyopathy (NICM), who often improve their ejection fraction (EF) during a prolonged period of time.[@euy091-B6] In the WEARIT-II Registry, the first prospective large registry of the WCD, there were a large number of patients with WCD use \>90 days, providing us with a unique opportunity for analysis.[@euy091-B7]

Therefore, the aim of the present sub-study of the WEARIT-II Prospective Registry on the WCD was (i) to assess the characteristics of prolonged WCD use \>90 days, (ii) to analyse ventricular arrhythmia events during WCD use, and to assess end of WCD use outcomes of either improvement in EF or ICD implantation in patients with WCD use ≤90 days vs. \>90 days, and (iii) to provide disease aetiology-specific information on WCD use ≤90 days vs. \>90 days and its outcomes.

Methods
=======

Patient population
------------------

All patients who were medically prescribed a WCD (LifeVest system, ZOLL, Pittsburgh, PA, USA) received an offer to participate in the Registry in the form of a recruitment letter included with the WCD, as reported previously.[@euy091-B7] Current indication for the use of the WCD has been outlined previously. In short, patients with low EF at risk for SCD after MI, following coronary revascularization (PCI/CABG), with new-onset dilated NICM, or with inherited or congenital heart disease (C/I) were prescribed the WCD for a temporary time period, while they were not candidates for an ICD. High risk for SCD included adult patients with significantly reduced left ventricular function 40 days following a MI, 90 days following a PCI or coronary artery bypass graft surgery (CABG), typically 90 days or longer for newly diagnosed non-ischaemic cardiomyopathy starting guideline directed medical therapy, as well as congenital/inherited heart disease patients at high risk for SCD (e.g. SCD in family history) during a time period of risk stratification (e.g. EPS testing, genetic testing). Recommendations for WCD use have been summarized by the AHA consensus document[@euy091-B2] and outlined by the 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of SCD.[@euy091-B8] Patients who agreed to participate were entered into the Registry after written informed consent. Patients in the Registry received standard medical treatment according to guidelines, and the Registry physicians were not involved in any medical care of the subjects. The University of Rochester, Rochester, NY, USA was the Coordination and Data Center for the WEARIT-II Registry, responsible for the overall study and data management of the Registry. The study protocol was approved by the Research Subjects Review Board at the University of Rochester, Rochester, NY, USA.

Data collection and follow-up
-----------------------------

Baseline medical history and comorbidities were collected through patient questionnaires at enrolment in the Registry. We also collected information on the indication for WCD use from the medical order forms. Further data were collected from the WCD devices, including arrhythmia events, WCD shocks delivered, and hours per day of WCD use. Follow-up questionnaires were sent to patients and physicians at 3 and 12 months post-enrolment. At the end of WCD use, patients were assessed for reasons for discontinuation, such as ICD implantation or EF improvement.

Definitions and endpoints
-------------------------

Patients were divided into two categories based on the duration of WCD use: WCD use ≤90 days, and \>90 days, using the actual wear time recorded in the Registry. This study focused on events during WCD use and end of use reasons at the end of WCD use.

Patients were assigned to the following subgroups based on disease aetiology: (i) patients who had ischaemic cardiomyopathy (ICM) with previous MI or known coronary artery disease with a high risk for SCD, (ii) patients who had a newly diagnosed non-ischaemic cardiomyopathy (NICM) with no known coronary artery disease, and (iii) patients who had congenital/inherited (C/I) heart disease with low EF and high risk for SCD.

The endpoints of the current study were ventricular arrhythmia events, such as sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) with or without WCD shock, and non-sustained VT events. At the end of the WCD use, we analysed ICD implantation rate vs. EF improvement by WCD use duration in the total population, as well as by disease aetiology. A number of patients had reasons 'other' than EF improvement or ICD implantation for WCD use termination. Other included cases when the WCD was returned due to condition deterioration, patient decision, insurance denial, death, non-compliance, skin condition, non-response, or WCD return without a specified reason.

Ventricular arrhythmia events
-----------------------------

A ventricular arrhythmia episode that was separated by 5 min from the previous event was considered a separate episode. Each individual ventricular arrhythmia episode was reviewed and adjudicated in the registry and classified into three major categories: (i) sustained VT (lasting 30 s or longer) or VF with WCD shock therapy, (ii) sustained VT with no WCD shock delivered due to the use of the response buttons in the case of haemodynamically stable/self-terminating VTs, and (iii) non-sustained VT of \<30 s in duration. Bradyarrhythmia events and inappropriate WCD shocks were rare, and they were not considered as endpoints for this analysis.

Statistical analysis
--------------------

Baseline clinical characteristics were compared between patients with WCD use ≤90 days, and \>90 days. Categorical variables were analysed using the χ^2^ or Fisher's exact test and were expressed as frequencies and percentages. Continuous variables were analysed using the non-parametric Rank-Sum Test, and were expressed as median and interquartile range, as appropriate.

Ventricular arrhythmia events were reported for patients with WCD use ≤90 days, and \>90 days by displaying the number and percentage of patients with each event. When comparing the incidence of ventricular arrhythmias, we calculated the number of events per 100 patient-years. Comparison of event rates was performed using negative binomial regression tests. Outcomes at the end of WCD use such as ICD implantation vs. EF improvement were expressed by WCD use ≤90 days vs. \>90 days as number and percentages and they were compared using the χ^2^ test.

Within ischaemic cardiomyopathy, non-ischaemic cardiomyopathy, and congenital/inherited heart disease patients, specific analyses were performed to assess the rate of arrhythmia events, as well as ICD implantation and EF improvement in patients with WCD use ≤90 days and \>90 days using the tests described above.

Analyses were performed using SAS 9.4 statistical software (Cary, NC, USA). All statistical tests performed were two-sided. A *P*-value of \<0.05 was considered statistically significant.

Results
=======

Of the 2000 patients included in the WEARIT-II registry, 981 patients (49%) used the WCD for greater than 90 days. Of patients with WCD use \>90 days, 494 patients (50%) had WCD use between 91--120 days, and 487 patients (50%) had WCD use \>20 days. Only a minority of patients used the WCD for over a year (*n* = 30, 1.5%) (*Figure [1](#euy091-F1){ref-type="fig"}*).

![Distribution of WCD use days in WEARIT-II. WCD, wearable cardioverter-defibrillator.](euy091f1){#euy091-F1}

Baseline clinical characteristics
---------------------------------

In the extended WCD use \>90 days group, patients more often had non-ischaemic cardiomyopathy compared to patients with WCD use ≤90 days (50% vs. 43%, *P* \< 0.001). Furthermore, extended WCD use patients more often reported heart failure symptoms at baseline, but they less often had atrial fibrillation, hyperlipidaemia, prior MI, or CABG. However, patients in the WCD ≤ 90 days group were older, with higher EF. Patients with prolonged WCD use were more often non-white, and interestingly, ACE/ARB and aldosterone antagonist use was more frequent in the prolonged WCD use group (*Table [1](#euy091-T1){ref-type="table"}*). Table 1Baseline clinical characteristics by WCD use 90 daysDemographicsWCD  ≤ 90 daysWCD  \> 90 daysP-valueNumber of patients1019981Aetiology: ischaemic (ICM)434 (43)371 (38)**0.03**Non-ischaemic (NICM)434 (43)493 (50)**\<0.001**Congenital/inherited (C/I)151 (15)117 (12)0.057Age63 (16)61 (17)**0.011**Female gender302 (30)296 (30)0.79White race901 (88)790 (81)**\<0.001**Ejection fraction30 (15)25 (15)**0.015**Hispanic31 (3)41 (4)0.39Daily use (h)22.2 (2.6)22.5 (3.3)**0.001**Heart failure at baseline481 (47)559 (57)**\<0.001**Atrial fibrillation316 (31)241 (25)**0.001**Hypertension635 (62)573 (58)0.07Hyperlipidaemia539 (53)456 (46)**0.004**Diabetes296 (29)255 (26)0.12Renal disease79 (8)83 (8)0.56Myocardial infarction479 (47)406 (41)**0.011**Percutaneous coronary angioplasty335 (33)275 (28)**0.019**CABG183 (18)139 (14)**0.021**Cardiomyopathy434 (43)465 (47)**0.031**Aldosterone antagonist243 (24)318 (32)**\<0.001**ACE-I/ARB714 (70)768 (78)**\<0.001**Beta-blockers871 (85)859 (88)0.17Amiodarone142 (14)117 (12)0.18[^1][^2]

Ventricular arrhythmia events by wearable cardioverter-defibrillator use duration
---------------------------------------------------------------------------------

In patients with WCD use \>90 days, there was a lower incidence of any sustained VT/VF (13 vs. 28 patients, 11 vs. 50 events per 100 patient-years, *P* \< 0.001), sustained VT events without treatment (10 vs. 12 patients, 10 vs. 32 events per 100 patient-years, *P* = 0.008), and sustained VT/VF treated with WCD shock (3 vs. 19 patients, 1 vs. 18 events per 100 patient-years, *P* \< 0.001) as compared to WCD use ≤90 days. Similarly, the incidence of non-sustained VT events was lower with WCD use \>90 days (51 vs. 21 events per 100 patient-years, *P* = 0.030) (*Table [2](#euy091-T2){ref-type="table"}*). When we assessed the timing of the events in patients with WCD use \>90 days, there were six patients with any sustained VT/VF before 90 days of use, and seven patients with any sustained VT/VF after 90 days. Five of the 10 patients had sustained VT events without treatment before 90 days, and the other five had them after 90 days. However, two of the three treated VT/VF events occurred past 90 days of use. Table 2Arrhythmia events during WCD use by ≤90 days vs. \>90 daysEventPatients, *n* (%)Events (mean events/ patient)Event rate per 100 patient-years*P*-value for ≤90 days vs. \>90 daysWCD use ≤90 days All sustained VT/VF28 (2.7)76 (2.7)50**\<0.001** Sustained VT no treatment12 (1.2)49 (4.1)32**0.008** Sustained VT treated19 (1.9)27 (1.4)18**\<0.001** NSVT12 (1.2)78 (6.5)51**0.030**WCD use \>90 days All sustained VT/VF13 (1.3)44 (3.4)11\<0.001 Sustained VT no treatment10 (1.0)41 (4.1)100.008 Sustained VT treated3 (0.3)3 (1)1\<0.001 NSVT16 (1.6)86 (5.4)210.030[^3][^4]

Ventricular arrhythmia events by wearable cardioverter-defibrillator use duration and by disease aetiology
----------------------------------------------------------------------------------------------------------

Among patients with ischaemic cardiomyopathy, those with WCD use \>90 days had a lower rate of sustained VT/VF (7 vs. 17 patients, 10.6 vs. 56.8 events per 100 patient-years, *P* = 0.001), and a lower rate of WCD treated VT/VF (3 vs. 6 patients, 9.3 vs. 35.3 events per 100 patient-years, *P* \< 0.001) as compared to WCD use ≤90 days. In patients with non-ischaemic cardiomyopathy, there was a similar rate of sustained VT/VF events in both the WCD use \>90 days and WCD use ≤90 days groups (5 vs. 5 patients, 13.4 vs. 13.7 events per 100 patient-years, *P* = 0.314); however, most of these events were self-terminating without WCD shocks. Congenital/inherited heart disease patients also had less sustained VT/VF events during WCD use \>90 days, and there were no WCD shocks in this group (*Tables [3](#euy091-T3){ref-type="table"}* and *[4](#euy091-T4){ref-type="table"}*). Table 3Ventricular arrhythmia events during WCD use ≤90 days by aetiologyPatients, *n* (%)Events (mean events/ patient)Event rate per 100 patient-years*P*-value for ≤90 days vs. \>90 daysIschaemic cardiomyopathy All sustained VT/VF17 (4.6)37 (2.2)56.8**0.001** Sustained VT no treatment6 (1.6)23 (3.8)35.30.074 Sustained VT treated13 (3.5)14 (1.1)21.5**\<0.001** NSVT3 (0.8)39 (13)59.80.063Non-ischaemic cardiomyopathy All sustained VT/VF5 (1.2)9 (1.8)13.70.314 Sustained VT no treatment2 (0.5)6 (3.0)9.10.543 Sustained VT treated3 (0.7)3 (1.0)4.60.055 NSVT5 (1.2)22 (4.4)33.50.541Congenital/inherited heart disease patients All sustained VT/VF6 (4)30 (5.0)135.9**0.003** Sustained VT no treatment4 (2.7)20 (5.0)90.6**0.013** Sustained VT treated3 (2)10 (3.3)45.3n.a. NSVT4 (2.6)17 (4.3)77.0**0.043**[^5][^6]Table 4Ventricular arrhythmia events during WCD use \>90 days by aetiologyPatients, *n* (%)Events (mean events/ patient)Event rate per 100 patient-years*P*-value for ≤90 days vs. \>90 daysIschaemic cardiomyopathy All sustained VT/VF7 (1.9)16 (2.3)10.6**0.001** Sustained VT no treatment5 (1.3)2 (0.4)1.30.074 Sustained VT treated2 (0.5)14 (7)9.3**\<0.001** NSVT5 (1.3)12 (2.4)7.90.063Non-ischaemic cardiomyopathy All sustained VT/VF5 (1)27 (5.4)13.40.314 Sustained VT no treatment4 (0.8)26 (6.5)12.90.543 Sustained VT treated1 (0.2)1 (1.0)0.50.055 NSVT7 (1.4)69 (9.9)34.30.541Congenital/inherited heart disease patients All sustained VT/VF1 (0.9)1 (1)2.0**0.003** Sustained VT no treatment1 (0.9)1 (1)2.0**0.013** Sustained VT treated0 (0)0 (0.0)0.0n.a. NSVT4 (3.4)5 (1.3)10.1**0.043**[^7][^8]

End-of-use outcomes by wearable cardioverter-defibrillator use duration
-----------------------------------------------------------------------

Among patients with WCD use ≤90 days, 33% were implanted with an ICD at the end of WCD use, while 47% of them had improvement in EF and were not implanted with an ICD. An additional 33% of the patients with prolonged WCD use \>90 days improved their EF avoiding the need to consider an ICD implantation (*Figure [2](#euy091-F2){ref-type="fig"}*). This additional observed improvement in EF beyond 90 days was similar for ischaemic (31%), non-ischaemic cardiomyopathy (34%), and congenital/inherited heart disease patients (30%) (*Figure [3](#euy091-F3){ref-type="fig"}*).

![Clinical outcomes at the end of WCD use by duration of WCD use. \**P* \< 0.001 for end of use category for patients with ≤90 days of total wear vs. \>90 days of total wear. EF, ejection fraction; ICD, received implantable cardioverter-defibrillator; WCD, wearable cardioverter-defibrillator.](euy091f2){#euy091-F2}

![Clinical outcomes at the end of WCD use by the duration of WCD use and by disease aetiology. \**P*-value \<0.001 for ≤90 vs. \>90 total days wear time. ^†^*P*-value \<0.001 in the ≤90 days wear time group for EOU by disease aetiology. C/I, congenital or inherited heart disease; EF, ejection fraction; EOU, end of use; ICD, implantable cardioverter-defibrillator; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic cardiomyopathy; WCD, wearable cardioverter-defibrillator.](euy091f3){#euy091-F3}

Discussion
==========

Our study provides several novel findings: (i) we characterized a large cohort of almost 1000 patients with WCD use \>90 days in a contemporary setting, (ii) demonstrated that patients with extended WCD use \>90 days remain at risk for ventricular arrhythmia events, (iii) reported that an additional one-third of the patients with WCD use \>90 days to improved their EF, and they were not implanted with an ICD, (iv) EF improvement was similar in patients with ischaemic and non-ischaemic cardiomyopathy, and (v) congenital/inherited heart disease patients less often improved their EF and were more often implanted with an ICD. These new findings altogether suggest that WCD use \>90 days could potentially improve risk stratification for an ICD in ischaemic and non-ischaemic cardiomyopathy patients.

Previous studies reported on the duration of WCD use and a number of these studies included patients who used the WCD for \>90 days. Chung *et al.*[@euy091-B5] showed an average 52.6 days of WCD use in the national aggregate experience of 3569 patients prescribed the WCD. In their study, only a small proportion of patients used the WCD for \>90 days, and they did not specifically report outcomes of the cohort with prolonged WCD use. In another study focusing on post-MI patients, Epstein *et al.*[@euy091-B9] showed an average of 69 days WCD use in 8453 patients, including time to first appropriate WCD shock as part of their analysis. They found that 96% of first appropriate shocks occurred within the first 90 days of use. However, this study focused only on patients prescribed the WCD within 3 months of an MI, they did not enrol patients with non-ischaemic cardiomyopathy.

So far, very few studies investigated WCD use and its outcomes past 90 days,[@euy091-B5]^,^[@euy091-B6] and some of these studies reported on longer use in specific subpopulations of cardiomyopathy, or in a very small number of patients.[@euy091-B10]^,^[@euy091-B11] The PROLONG study by Duncker *et al.*[@euy091-B12] evaluated prolonged WCD use in 74 of 156 patients, 12 of these patients had WCD shocks, two of them past 90 days of use. Similar findings were revealed in a subsequent report from the same group, focusing on non-ischaemic cardiomyopathy patients only.[@euy091-B13] In the WEARIT-II Registry, we had almost 1000 subjects, and half of our patients were using the WCD for longer than 90 days. And while the majority of the patients in the WCD use \>90 days subgroup had less than 6 months of WCD use duration, our study is the largest to date to report on patients with prolonged WCD use.

Why is our study clinically relevant? We have shown that extended WCD use was associated with a decision of not to implant an ICD in one-third of these patients with ischaemic or non-ischaemic cardiomyopathy. It is conceivable that patients with extended WCD use had a longer time for therapy optimization and left ventricular function recovery as compared to those with WCD use ≤90 days. And although ICDs are lifesaving devices for patients with permanent high risk for SCD, they are associated with an increased risk for lead failure, infection, and inappropriate shocks that could impair quality of life and outcomes, and increase health care costs.[@euy091-B14] Therefore, improved risk stratification with extended WCD use in high-risk cardiomyopathy patients could have cost benefits. Although we do not have detailed data on costs in the WEARIT-II registry, the WCD has been previously shown to be cost-effective in post-MI patients,[@euy091-B19] and following an ICD infection.[@euy091-B2]

In this sub-study from WEARIT-II, we have shown that at-risk cardiomyopathy patients remain at risk for ventricular arrhythmias during extended WCD use. While the risk of ventricular arrhythmias was shown to be lower for the WCD use \>90 days group, it is not a negligible risk. Non-ischaemic cardiomyopathy patients presented with similar rates of sustained VT/VF events with WCD use ≤ 90 days and \> 90 days although most of these events were self-terminated. Nevertheless, even self-terminating events are useful in facilitating the decision for an ICD implantation as we have previously shown in the primary report of WEARIT-II.[@euy091-B7] A total of 65% of patients with sustained VT events not requiring WCD shock were implanted with an ICD at the end of WCD use. This highlights the potential role of the WCD in not only protecting patients from SCD but also monitoring sustained VT events, and such events are useful for risk stratification.

Prolonged WCD use was associated with similar improvement in EF in both ischaemic and non-ischaemic cardiomyopathy patients suggesting that the myocardial substrate is yet to change with longer time for therapy optimization. Patients with congenital/inherited heart disease however had similar rates of EF improvement and ICD implantation with both ≤90 days and \>90 days. Whether left ventricular function would further improve with longer WCD use over 6 months or over a year is not fully understood. A prior small study on WCD use \>1 year among 220 patients reported 16% of these patients to have EF recovery, and 4.1% to receive an appropriate WCD shock.[@euy091-B20]

Our data on extended WCD use and its outcomes can aid physicians with patient management. Clinicians using the WCD in ischaemic and non-ischaemic cardiomyopathy patients could consider extended use of the WCD in patients in whom there were no ventricular arrhythmia events or EF recovery, especially when therapy optimization is still underway. An extended WCD use strategy for ICD risk stratification however needs to be prospectively assessed. A prospective clinical study assessing extended WCD use outcomes including ventricular arrhythmia rates, ICD implantation, and EF improvement, would provide further insights into additional risk stratification for an ICD. Such a study might be warranted in both patients with ischaemic and non-ischaemic cardiomyopathy, since both of these cohorts showed further EF improvement in our study.

Limitations
-----------

Our study nevertheless has certain limitations. The WEARIT-II registry is a voluntary, observational registry, patients were not randomized, and there was no control group. The registry mainly relied on direct patient reported data collected through surveys that have inherent limitations. However, days of wear and events while using the WCD were recorded from data collected from the WCD devices and were consistently reported for all patients in the registry. In patients with extended WCD use, we did not have detailed information on physician decision for longer use, and such decisions could have been influenced by other factors, such as difficulty in scheduling ICD implantation, changes in patient condition, or patient preferences. Collecting such information might be useful in future studies. As physician decision regarding prolongation of WCD use was not standardized, individual clinical scenarios might have played a role that could affect outcomes, introducing bias for comparison. We did not have detailed information on the specific aetiology of the non-ischaemic patient group. Finally, fewer than 10% of patients in the WEARIT-II registry wore the WCD for \>6 months, making it difficult to draw conclusions about extended WCD use \>6 months.

Conclusions
===========

In the WEARIT-II Registry, almost half of the patients had an extended WCD use \>90 days. Patients chosen by their physicians for an extended WCD use \>90 days remained at risk for ventricular arrhythmias \>90 days. In non-ischaemic cardiomyopathy patients, the rate of sustained VT events was similar with standard or extended WCD use, while most of these events were self-terminating. Approximately one-third of ischaemic and non-ischaemic cardiomyopathy patients with WCD use \>90 days had an EF improvement, avoiding the need to consider an ICD implantation. Further research is warranted to investigate the utility of prolonged WCD use past 90 days of use with detailed assessment of extended use decisions in ischaemic and non-ischaemic patients.

The authors would like to dedicate this work to the beloved memory of Dr Arthur J. Moss, the pioneer of WCD therapy. His early research work on the WEARIT/BIROAD study establishing the safety and efficacy of the WCD led to the subsequent FDA approval of the WCD and the widespread use of this novel technology temporarily protecting at-risk cardiac patients from SCD during a time of risk stratification.
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[^1]: Data are expressed as number and percentages and median and interquartile ranges. *P*-values \< 0.05 are highlighted in bold.

[^2]: ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; C/I, congenital or inherited condition; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic cardiomyopathy; WCD, wearable cardioverter-defibrillator.

[^3]: *P*-values \< 0.05 are highlighted in bold.

[^4]: NSVT, non-sustained ventricular tachycardia; VT/VF, ventricular tachycardia/ventricular fibrillation; WCD, wearable cardioverter-defibrillator.

[^5]: *P*-values \< 0.05 are highlighted in bold.

[^6]: NSVT, non-sustained ventricular tachycardia; VT/VF, ventricular tachycardia/ventricular fibrillation; WCD, wearable cardioverter-defibrillator.

[^7]: *P*-values \< 0.05 are highlighted in bold.

[^8]: NSVT, non-sustained ventricular tachycardia; VT/VF, ventricular tachycardia/ventricular fibrillation; WCD, wearable cardioverter-defibrillator.
